NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00117845 2019-11-19
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01724177 2018-05-29
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Celgene
Phase 2 Completed
NCT01173887 2017-03-30
Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00920790 2017-03-29
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01274533 2016-05-23
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Columbia University
Phase 2 Completed
NCT00699296 2012-11-27
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Novartis
Phase 2 Terminated
NCT00061048 2012-10-31
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed